Abstract. Coorevits P, Sundgren

Through a combination of a consortium that brings collectively many years of experience from previous relevant EU projects and of the global conduct of clinical trials, of an approach to ethics that engages many important stakeholders across Europe to ensure acceptability, of a robust iterative design methodology for the platform services that is anchored on requirements of an underlying Service Oriented Architecture that has been designed to be scalable and adaptable, EHR4CR could be well placed to deliver a sound, useful and well accepted pan-European solution for the reuse of hospital EHR data to support clinical research studies.

The ability to identify early life-history stages of organisms is essential for a better understanding of population dynamics and for attempts to inventory biodiversity. The morphological identification of larvae is time consuming and often not possible in those species with early lifehistory stages that are radically different from their adult counterparts. Molecular methods have been successful in identifying marine larvae; however, to date these methods have been destructive. We describe here an in situ hybridisation (ISH) technique that uses oligonucleotide probes specific for the 18S ribosomal RNA gene to identify marine larvae. Our technique leaves the larvae intact, thus allowing the description of larvae whose morphology was not previously known. Only 1 mismatch between the rRNA sequences of target and non-target species is sufficient to discriminate species, with nearly 100% efficiency. We developed a colourimetric assay that can be detected with a dissecting microscope, and is thus suitable for autofluorescent or large eggs and larvae that cannot be sorted under a microscope. Probe binding is revealed by an enzymatic reaction catalysed by either a horseradish peroxidase or an alkaline phosphatase. ISH was broadly applicable: it was effective in identifying eggs, larvae and adult tissues, soft-bodied larvae (polychaetes) and larvae with hard shells (bivalves), larvae belonging to different phyla and from different environments. Further advantages of this method are its relatively low cost, that only a minimal amount of equipment is needed, and that 100s of specimens can be processed quickly and simultaneously.

No abstract

FGFR1 is a receptor tyrosine kinase of which the ligands belong to the fibroblast growth factor family. To evaluate the significance of FGFR1 in lung cancer, we analysed tumours by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Tissue microarrays were constructed containing 380 lung cancer samples including squamous cell carcinomas (SCC), adenocarcinomas (ADC), non-small cell lung cancer not otherwise specified, metastases, neuroendocrine tumours, large cell lung cancer and small cell lung cancer. FGFR1 expression was analysed by IHC and scored semi-quantitatively by a four-tier approach (0, 1, 2, 3). Using dual-colour interphase FISH with probes specific for the locus on 8p12 and the centromere of chromosome 8 (CEN8), copy numbers of FGFR1 were determined. High expression of FGFR1 was associated with increased FGFR1 gene copy numbers in squamous cell carcinoma (p < 0.001). The FGFR1 locus was equally affected by copy number losses and gains. The higher FGFR1 gene copy numbers in SCC compared to ADC did not reach statistical significance. High copy number amplification of FGFR1 was a very rare event, the FGFR1/CEN8 signal ratio reaching a maximum value of 2.75. There were no significant associations between FGFR1 and clinicopathological parameters. Fibroblast growth factor signalling represents an interesting therapeutic target in lung cancer. However, the pathways are complex with potential oncogenic and anti-oncogenic activities. Our data may help to define criteria for selecting patients that may benefit from these new therapeutic options.